$92.21+0.83 (+0.91%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Transmedics Group (TMDX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~111.5%/yr (FY21→FY25), net margin 31.4%; free cash flow runs at 70% of net income. Check the accrual gap. Worth your attention in FY25: Share count (+46.8%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲37.1%
605.5
FY21→FY25CAGR +111.5%/yr
Net income ($M)▲436.6%
190.3
one-off year: see footnoteCAGR —
Free cash flow ($M)—
133.6
FY21→FY25CAGR —
Diluted EPS▲382.2%
4.87
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+46.8%
27.6mn → 40.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$59.3M
−54.3% YoY in FY25 · 9.8% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
31¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 69.9% → 59.9%. Net margin 31.4% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 727,650.0 | 605,494.0 | 441,540.0 | 241,623.0 | 93,459.0 | 30,262.0 | ▲37.1% | +111.5% |
Cost of revenue | 301,220.0 | 242,688.0 | 179,459.0 | 87,530.0 | 28,187.0 | 9,103.0 | ▲35.2% | +127.2% |
Gross profit | 426,430.0 | 362,806.0 | 262,081.0 | 154,093.0 | 65,272.0 | 21,159.0 | ▲38.4% | +103.5% |
Research & development | 106,394.0 | 69,055.0 | 55,968.0 | 63,267.0 | 26,812.0 | 22,304.0 | ▲23.4% | +32.6% |
Selling, general & admin | 233,589.0 | 185,168.0 | 168,617.0 | 119,553.0 | 69,897.0 | 38,283.0 | ▲9.8% | +48.3% |
Total operating expenses | 339,983.0 | 254,223.0 | 224,585.0 | 182,820.0 | 96,709.0 | 60,587.0 | ▲13.2% | +43.1% |
Operating incomefeeds ROC rank | 86,447.0 | 108,583.0 | 37,496.0 | −28,727.0 | −31,437.0 | −39,428.0 | ▲189.6% | — |
Other income, net | −12,823.0 | −1,061.0 | −1,716.0 | 2,056.0 | −4,728.0 | −4,751.0 | — | — |
Pretax income | 73,624.0 | 107,522.0 | 35,780.0 | −26,671.0 | −36,165.0 | −44,179.0 | ▲200.5% | — |
Income tax | −70,829.0 | −82,769.0 | 316.0 | −1,643.0 | 66.0 | 36.0 | — | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 144,453.0 | 190,291.0 | 35,464.0 | −25,028.0 | −36,231.0 | −44,215.0 | ▲436.6% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 3.66 | 4.87 | 1.01 | −0.77 | −1.23 | −1.60 | ▲382.2% | — |
Diluted shares (mn) | 40.83 | 40.54 | 35.22 | 32.52 | 29.56 | 27.62 | ▲15.1% | +10.1% |
| Margins | ||||||||
Gross margin39th pct in Healthcare | 58.6% | 59.9% | 59.4% | 63.8% | 69.8% | 69.9% | ▲0.6pp | −10.0pp |
Operating margin | 11.9% | 17.9% | 8.5% | −11.9% | −33.6% | −130.3% | ▲9.4pp | +148.2pp |
Net margin85th pct in Healthcare | 19.9% | 31.4% | 8.0% | −10.4% | −38.8% | −146.1% | ▲23.4pp | +177.5pp |
† TTM = trailing four quarters through 2026-09-30.FY25 effective tax rate was −77% vs a −0% norm for this window, likely a one-time item; see the filing.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Transmedics Group's revenue last fiscal year?
Transmedics Group reported revenue of $605.5M in fiscal 2025, up 37.1% from fiscal 2024.
What was Transmedics Group's net income?
Transmedics Group reported net income of $190.3M in fiscal 2025, a net margin of 31.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

